Oncology and Carcinogenesis articles for Italy

Time frame: 1 June 2025 - 30 May 2026

View topic

Count: 305

Article ‘Count’ for Oncology and Carcinogenesis.

Journal Count Share
2 1.67
Citrate-functionalised hydroxyapatite mimics the microenvironment of bone metastases and demonstrates the role of citrate in prostate cancer colonization of bone 0.86
Insights into the osteosarcoma microenvironment: Multiscale analysis of structural and mineral heterogeneity 0.81
1 0.15
Body size and occupational physical activity during the life course and gastrointestinal cancers 0.15
1 0.35
Bi-allelic loss-of-function variants in JKAMP cause a neurodevelopmental syndrome associated with dysregulation of GPR37 trafficking 0.35
1 0.23
Assessing Acetyl-Coenzyme A Carboxylase Activity and Inhibition in iCaenorhabtidis elegans/i Using a Partially Purified Protein Extract 0.23
3 0.32
Fullerene Photosensitization Within a Self-Assembled Hollow Pd (II) Architecture for Light-Driven Oxidation Reactions in Water 0.25
Esterase-Responsive Mitochondria-Targeted Hydropersulfide Donors Mitigate Doxorubicin Cardiotoxicity While Preserving Anticancer Activity 0.05
Fragment‐Based Drug Discovery of Novel High‐affinity, Selective, and Anti‐inflammatory Inhibitors of the Keap1‐Nrf2 Protein‐Protein Interaction 0.02
7 2.94
The International Study Group for Pancreatic Surgery (ISGPS) Definition and Classification of Postpancreatectomy Mortality. 0.18
Setting the Standard in Robotic Whipple Surgery: International Multicenter Benchmark Analysis. 0.08
Impact of Celiac Axis Stenosis in Patients Undergoing Pancreatoduodenectomy and Total Pancreatectomy: International Multicenter Study. 0.21
Accuracy of Histology and Malignancy Grade between Preoperative Biopsy and Surgical Specimens in Primary Retroperitoneal Sarcoma. A Study from the Prospective Retroperitoneal Sarcoma Registry (Resar). 0.32
Prognostic Validation of Perineural Invasion Severity Score in Pancreatic Cancer: A Prospective Study. 1.00
Pancreaticojejunostomy Versus Neoprene-based Pancreatic Duct Occlusion in Pancreaticoduodenectomy for Patients at Intermediate-high Risk of Post-operative Pancreatic Fistula: A Comparative Cohort Study. 1.00
Recommendations on Perihilar Cholangiocarcinoma. The Milan Jury-Based Consensus. 0.15
1 0.06
Differential molecular signatures in response to CD19-CAR T cell therapy compared with conventional pharmacotherapy in systemic lupus erythematosus 0.06
14 2.94
PU.1-activated genomic regions define low-risk MDS subsets characterized by immune dysregulation and disease progression 1.00
Long-term efficacy and safety results of betibeglogene autotemcel gene therapy for transfusion-dependent β-thalassemia 0.04
Common variation at 1q23.3, 2p23.3, 2q33.3, and 2p21 influences the risk of acute myeloid leukemia 0.04
Harnessing the CD2 axis to broaden and enhance the efficacy of CAR T-cell therapies 0.04
Menin inhibition with revumenib for iNPM1/i-mutated relapsed or refractory acute myeloid leukemia: the AUGMENT-101 study 0.06
ZUMA-8: a phase 1 study of brexucabtagene autoleucel in patients with relapsed/refractory chronic lymphocytic leukemia 0.07
Type 2 calreticulin mutations activate ATF6 to promote BCL-xL–mediated survival in myeloproliferative neoplasms 0.21
BLAST: A Globally Applicable and Molecularly Versatile Survival Model for Chronic Myelomonocytic Leukemia 0.06
The ENHANCE-3 study: venetoclax and azacitidine plus magrolimab or placebo for untreated AML unfit for intensive therapy 0.05
Magrolimab plus azacitidine vs physician’s choice for untreated iTP53/i-mutated acute myeloid leukemia: the ENHANCE-2 study 0.05
A BCMA-mRNA vaccine is a promising therapeutic for multiple myeloma 0.10
Fusion Oncoproteins and Cooperating Mutations Define Disease Phenotypes in NUP98-Rearranged Leukemia 0.22
Loss of BCL7A permits IRF4 transcriptional activity and cellular growth in multiple myeloma 0.08
Aberrant single-cell phenotype and clinical implications of genotypically defined polyclonal plasma cells in myeloma 0.93
1 0.10
De novo and inherited variants in DDX39B cause a novel neurodevelopmental syndrome 0.10
2 0.18
Management of gastric cancer peritoneal metastasis: International Gastric Cancer Association GCPM Working Group consensus statements 0.12
Axillary dissection for low-volume nodal involvement after neoadjuvant therapy in breast cancer: multicentre AXSANA cohort study 0.06
4 1.00
Multi-omic landscape of human gliomas from diagnosis to treatment and recurrence 0.01
Restraint of cancer cell plasticity by spatial homotypic clustering 0.03
Myeloid cell networks govern re-establishment of original immune landscapes in recurrent ovarian cancer 0.05
Cisplatin and temozolomide combinatorial treatment triggers hypermutability and immune surveillance in experimental cancer models 0.91
11 2.83
A Double-Negative Prostate Cancer Subtype Is Vulnerable to SWI/SNF-Targeting Degrader Molecules 0.06
Catalytic Inhibition of p300 Preferentially Targets IRF4 Oncogenic Activity and Tumor Growth in Multiple Myeloma. 0.04
Mitochondrial Transfer Rescues Respiration to Support De Novo Pyrimidine Biosynthesis and Tumor Progression. 0.11
An Extracellular Matrix-Producing Subset of Cancer-Associated Fibroblasts Drives Chemoresistance in Breast Cancer via SRC Activation and G0S2 Upregulation. 0.13
ESR1 Activating Mutations Confer Metabolic Vulnerabilities in ER+ Breast Cancer. 0.86
In Silico Digital Twins of Bone Metastasis Enable Investigation of Tumor Progression and Therapy Response 0.25
FNDC4 Drives Metastasis and Immune Evasion in Pancreatic Cancer. 0.28
CRISPR–Drug Combinatorial Screening Identifies Effective Combination Treatments for MTAP-Deleted Cancer 0.02
HPV E5 Mediates Resistance to Chemotherapy and Radiation by Promoting a Stem Cell-Like Phenotype in Head and Neck Squamous Cell Carcinoma. 0.10
AREG and EREG Are Predictive Biomarkers of Response to EGFR Inhibition in Gastroesophageal Cancer 0.95
Carbonic Anhydrase Inhibition Sensitizes Group 3 Medulloblastoma to Radiotherapy 0.01
2 0.17
Biodiversity and biogeography of the multi-kingdom cancer microbiome 0.14
Longitudinal ultrasensitive ctDNA monitoring for high-resolution lung cancer risk prediction 0.03
2 0.27
Long-lasting gut microbiome and fecal metabolome alterations after colorectal adenoma removal and their relationship to colorectal cancer 0.13
Intratumoral microbiota and host genotype cooperatively shape neutrophil cytotoxic functions in colorectal cancer 0.14
1 1.00
Fibrous zeolites and pulmonary fibroblasts: toxicological impact and EPR-based insights into cellular alterations 1.00
1 1.00
Life’s Simple 7 score and cardiovascular health in cancer survivors: the Moli-sani study 1.00
6 2.46
Bladder Cancer Incidence and Mortality: A Global Overview and Recent Trends 0.25
Primary Noncontrast Magnetic Resonance Imaging for Prostate Cancer Screening: A Randomized Clinical Trial (PROSA) 0.95
Association Between the PRIMARY Score at Staging Prostate-specific Membrane Antigen Positron Emission Tomography and Overall Survival Among Patients with Newly Diagnosed Prostate Cancer: Findings from the International, Multicenter PROMISE Registry 0.11
Artificial Intelligence 3D Augmented Reality–guided Robotic Prostatectomy Versus Cognitive MRI Intervention: Results of the Prospective Randomized RIDERS Trial 1.00
Erdafitinib in Patients with High- and Intermediate-risk Non–muscle-invasive Bladder Cancer: Final Analysis of THOR-2 Study 0.10
Cost-effectiveness Analysis of Treatments for Bacillus Calmette-Guérin–unresponsive Carcinoma in Situ of the Bladder 0.05
2 0.08
An Exosome-Based Liquid Biopsy for the Detection of Early-Onset Colorectal Cancer: The ENCODER Multicenter Study 0.03
Validation of a Serum-Based Biomarker Signature for Detection of Early-Stage Pancreatic Ductal Adenocarcinoma 0.05
3 1.33
Spatial profiling of patient-matched HER2 positive gastric cancer reveals resistance mechanisms to targeted therapy 0.26
Immunosuppressive contribution of tumour-infiltrating B cells in human intrahepatic cholangiocarcinoma and their role in chemoimmunotherapy outcome 1.00
Role of CNNM4 in the progression of cholangiocarcinoma: implications for ferroptosis and therapeutic potential 0.07
5 1.64
Long-term outcomes of atezolizumab-bevacizumab in unresectable hepatocellular carcinoma: A real-world study. 0.93
Hepatocellular carcinoma with macrovascular invasion: Review and survival meta-analysis of initial local therapy using minimal prognostic criteria. 0.09
A multicenter dose-defining/expansion phase 1b study of first-line regorafenib plus pembrolizumab in patients with advanced hepatocellular carcinoma. 0.06
Satellite lesions versus intrahepatic metastasis in multifocal intrahepatic cholangiocarcinoma: Prognostic impact and genomic profiling. 0.05
Refinement of histologic subtypes and identification of biomarkers linked to unfavorable prognosis in cholangiocarcinoma: The ENSCCA registries' framework for digital twin advancement. 0.51
1 0.11
Carboplatin and paclitaxel induced-gonadotoxicity on the ovarian reserve of young breast cancer patients with BRCA1 mutation 0.11
1 0.03
Immune signature-based uncoupling of checkpoint inhibitor efficacy and toxicity 0.03
1 0.71
Heavy Alkaline Earth Radiometals for Cancer Theranostics: Coordination and Radiochemistry of Radium-223 and Barium-131 with Kryptofix 22-Based Chelators 0.71
4 2.71
Development and validation of an epidemiological risk score for early detection of pancreatic cancer in high-risk individuals within the IMAGene project 0.30
Spatio-temporal trends in pleural mesothelioma mortality in Italy: a 40-year analysis by calendar period and birth cohort 1.00
Body mass index and gastric cancer risk: results from the Stomach Cancer Pooling Project Consortium 0.40
Mammography screening and incidence of ductal carcinoma iin situ/i of the breast in Italy: an age-period-cohort analysis 1.00
3 0.76
Activity and Physiological Stress Within 90 Days After Minimally Invasive and Open Pancreatoduodenectomy: A Predefined Analysis of the DIPLOMA-2 Randomized Clinical Trial. 0.23
International Reference Values for Surgical Outcomes of Total Pancreatectomy 0.20
Minimally Invasive vs Open Left Pancreatectomy for Resectable Pancreatic Cancer 0.33
1 0.12
Biparametric vs Multiparametric MRI for Prostate Cancer Diagnosis 0.12
1 0.91
A cryptic-site ligand stabilizes a non-canonical interface and blocks membrane insertion of the chloride intracellular channel CLIC1 0.91
4 3.23
Molecular Profile of Advanced Radioiodine-refractory Thyroid Cancer and Response to Lenvatinib Treatment 1.00
Age-specific risk of malignancy in pediatric thyroid cytology: Reframing ROM based on pre-test probability 0.23
Calcitonin thresholds for prediction of medullary thyroid carcinoma and its clinical response in MEN2A gene carriers 1.00
Endocrine disorders after treatment for pediatric brain tumors: long-Term outcomes and risk factors 1.00
10 2.77
Inhibition of ceramide synthesis ameliorates body wasting in a cancer cachexia model 0.17
ER-associated degradation pathway protein SEL1L plays an evolutionarily conserved role in platelet adhesion 0.29
Mutated FGFR1 is an oncogenic driver and therapeutic target in high-risk neuroblastoma 0.02
SH3BP5L triggers the RAB11A-regulated integrin recycling network implicated in breast cancer metastasis 0.91
CD8+ T cells in the tumor microenvironment modulate response to endocrine therapy in breast cancer 0.10
Tissue-specific anti-tumor NK cell subsets identified in colorectal cancer liver metastases express candidate therapeutic targets 0.96
Androgen deprivation-mediated activation of AKT is enhanced in prostate cancer with TMPRSS2:ERG fusion 0.02
Personalized treatment in HPV+ oropharynx cancer using genomic adjusted radiation dose 0.17
PTBP1 variants displaying altered nucleocytoplasmic distribution are responsible for a neurodevelopmental disorder with skeletal dysplasia 0.04
Mutations in spliceosomal gene SNW1 cause neurodevelopment disorders with microcephaly 0.08
35 5.66
Overall Survival Among Patients With Hepatocellular Carcinoma Treated With External Beam Radiation Therapy: Individual Patient Data Outcomes From a Multinational Cohort 0.03
Malignant Adult Ovarian Germ Cell Tumors: An International Multicenter Study to Identify Relevant Prognostic Risk Factors for Stage IC and Beyond. 0.42
Amivantamab Monotherapy in Chemorefractory RAS/BRAF Wild-Type Metastatic Colorectal Cancer: Results From OrigAMI-1, an Open-Label, Phase Ib/II Study. 0.02
Phase I Study of Mosperafenib, a Novel Paradox Breaker B-Raf Proto-Oncogene Serine/Threonine Kinase (BRAF) Inhibitor, in Patients With BRAF V600-Mutant Solid Tumors. 0.02
Residual Absolute Volume of Blastema as a Predictor of Clinical Outcomes in Patients With Wilms Tumor: A Report From the SIOP WT 2001 Study. 0.05
Pembrolizumab With or Without Lenvatinib as First-Line Therapy for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Phase III LEAP-010 Study. 0.00
VIKTORIA-1 Trial of Gedatolisib Plus Fulvestrant With or Without Palbociclib in Hormone Receptor-Positive/HER2-/PIK3CA Wild-Type Advanced Breast Cancer. 0.04
Risk of Breast Cancer After Ovarian Cancer in Women With a Pathogenic/Likely Pathogenic Variant in BRCA1 or BRCA2. 0.06
Impact of Circulating Tumor DNA and Copy-Number Alterations on Clinical Outcome in Relapsed/Refractory Germ Cell Tumors Treated With Salvage High-Dose Chemotherapy. 0.67
Pivekimab Sunirine in Blastic Plasmacytoid Dendritic Cell Neoplasm. 0.17
Pharmacokinetics and Safety of Selumetinib Granule Formulation in Children With Symptomatic, Inoperable Neurofibromatosis Type 1-Related Plexiform Neurofibromas (SPRINKLE; phase I/II). 0.08
Marking Techniques for Target Lymph Nodes in Node-Positive Breast Cancer Treated With Neoadjuvant Therapy in the AXSANA/EUBREAST-03/AGO-B-053 Study. 0.06
Extended Endocrine Therapy Following 5 Years of Adjuvant Luteinizing Hormone-Releasing Hormone Agonist in Premenopausal Patients With Node-Positive, Hormone Receptor-Positive Breast Cancer: A Cohort Study. 0.76
Adjuvant Durvalumab in Completely Resected Early-Stage Non-Small Cell Lung Cancer. 0.07
Dinutuximab Beta Added to Temozolomide-Based Chemotherapy for Children With Relapsed and Refractory Neuroblastoma: Results of the ITCC-SIOPEN BEACON Immuno Phase II Trial. 0.02
Venetoclax-Dexamethasone Versus Pomalidomide-Dexamethasone in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma: Primary Results of the Randomized, Phase III CANOVA Study. 0.04
HER2CLIMB-05: A Phase 3 Study of Tucatinib Versus Placebo in Combination with Trastuzumab and Pertuzumab as First-line Maintenance Therapy for HER2+ Metastatic Breast Cancer. 0.05
Gemcitabine intravesical system plus cetrelimab or cetrelimab alone as neoadjuvant therapy in patients with MIBC: primary analysis and biomarker results of SunRISe-4. 0.05
STELLAR: Phase III, Randomized, Open-Label Study of Eflornithine Plus Lomustine Versus Lomustine Alone in Patients With Recurrent Grade 3 Astrocytoma. 0.14
Individual Patient Data Meta-Analysis of Consensus Molecular Subtypes as Biomarkers of First-Line Treatment in RAS Wild-Type Metastatic Colorectal Cancer. 0.09
Reducing Daunorubicin in Induction Therapy in Children With B-Lineage ALL With Favorable Prognosis: Results of Phase III Trial AIEOP-BFM ALL 2009. 0.29
First-in-Human, Phase I/II Dose Escalation and Expansion Study of Zelenectide Pevedotin in Patients With Advanced Solid Tumors: Results From Monotherapy Dose Escalation. 0.05
TRYBECA-1: A Randomized Phase III Study of Eryaspase Combined With Chemotherapy Versus Chemotherapy as Second-Line Treatment in Patients With Advanced Pancreatic Adenocarcinoma. 0.06
Neoadjuvant CTLA-4/PD-(L)1 Blockade Versus Surgery +/- Chemotherapy in Deficient Mismatch Repair/Microsatellite Instability-High Resectable Gastroesophageal Adenocarcinoma: Individual Patient Data Pooled Analysis. 0.56
Ziftomenib in Relapsed or Refractory NPM1-Mutated AML. 0.03
Phase II Dose-Randomized Study of Sunvozertinib in Platinum-Pretreated Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor Exon 20 Insertion Mutations (WU-KONG1B). 0.13
Impact of Human Epidermal Growth Factor Receptor 2 in Patients With Metastatic Colorectal Cancer Treated With Chemotherapy Plus Bevacizumab or Anti-EGFRs: Exploratory Analysis of Eight Randomized Trials. 0.45
Xevinapant or Placebo Plus Platinum-Based Chemoradiotherapy in Unresected Locally Advanced Squamous Cell Carcinoma of the Head and Neck (TrilynX): A Randomized, Phase III Study. 0.05
Is There a Role for Mifamurtide in Nonmetastatic High-Grade Osteosarcoma? Results From the Italian Sarcoma Group (ISG/OS-2) and Spanish Sarcoma Group (GEIS-33) Trials. 0.69
Arsenic Trioxide and All-Trans Retinoic Acid Combination Therapy for the Treatment of High-Risk Acute Promyelocytic Leukemia: Results From the APOLLO Trial. 0.27
TAR-200 for Bacillus Calmette-Guérin-Unresponsive High-Risk Non-Muscle-Invasive Bladder Cancer: Results From the Phase IIb SunRISe-1 Study. 0.09
Primary Analysis of EPIK-O/ENGOT-ov61: Alpelisib Plus Olaparib Versus Chemotherapy in Platinum-Resistant or Platinum-Refractory High-Grade Serous Ovarian Cancer Without BRCA Mutation. 0.09
Efficacy and Safety of Avutometinib ± Defactinib in Recurrent Low-Grade Serous Ovarian Cancer: Primary Analysis of ENGOT-OV60/GOG-3052/RAMP 201. 0.04
Isatuximab Subcutaneous by On-Body Delivery System vs Isatuximab Intravenous Plus Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Phase 3 IRAKLIA Study. 0.03
Zipalertinib in Patients With Epidermal Growth Factor Receptor Exon 20 Insertion-Positive Non-Small Cell Lung Cancer Previously Treated With Platinum-Based Chemotherapy With or Without Amivantamab. 0.04
1 0.13
The assembly of cancer-specific ribosomes by the lncRNA LISRR suppresses melanoma anti-tumor immunity 0.13
3 1.33
Molecular profiling and matched targeted treatment in cholangiocarcinoma: results from the Italian dataset (ANITA) 1.00
Rapid whole-blood immune profiling reveals heterogeneous HBV-specific T cell response patterns independent of clinical disease phases 0.17
Association of candidate surrogate endpoints with overall survival in advanced biliary tract cancer 0.17
1 0.10
Validation of PARACELSUS score performance for the diagnosis of pyoderma gangrenosum: An international multicenter study with 1403 cases 0.10
1 0.06
π-Extended Ru–COUBPY Photosensitizers for In Vivo Anticancer Phototherapy Using One-Photon 780 nm Near-Infrared Light 0.06
9 2.75
The benefit of adjuvant pertuzumab and trastuzumab according to estrogen receptor and HER2 expression: a Sub-analysis of the APHINITY trial 0.23
Temporal Patterns and Factors Associated with Early Termination in Phase 1 Clinical Trials for Solid Tumors 0.88
A smoking-related plasma protein score and smoking-related cancer risk and mortality in ARIC 0.04
<atl>Impact of iKRAS/i codon-specific mutations on survival in metastatic CRC on trifluridine-tipiracil with/without bevacizumab</atl> 0.11
Assessing the oncologic risk when systematic and multiparametric magnetic resonance imaging-targeted prostate biopsy grade groups are discordant 0.23
Outcomes of subsequent treatment regimens after trastuzumab deruxtecan in patients with metastatic breast cancer 0.02
Aprepitant use during chemotherapy and association with survival in women with early breast cancer 0.27
Breastfeeding after breast cancer in young iBRCA/i carriers 0.33
The impact of molecular alterations in patients with advanced biliary tract cancer receiving cisplatin, gemcitabine and durvalumab: a large real-life worldwide population 0.64
1 0.13
A predictor finding study found patient-reported outcomes improve the prediction of mortality of incident dialysis patients 0.13
4 1.90
Damage-induced i-loops generate eccDNA from repetitive elements 1.00
The E3 ligase RNF32 controls the IκB kinase complex and NF-κB signaling in intestinal stem cells 0.70
Targeted citrullination enables p53 binding to non-canonical sites 0.05
Condensin II activation by M18BP1 0.15
6 0.71
Evolutionary characterization of lung cancer metastasis 0.00
Homologous recombination deficiency and hemizygosity drive resistance in breast cancer 0.03
Uncovering the role of LINE-1 in the evolution of lung adenocarcinoma 0.07
Anti-progestin therapy targets hallmarks of breast cancer risk 0.06
Structural basis for mTORC1 activation on the lysosomal membrane 0.52
The mutagenic forces shaping the genomes of lung cancer in never smokers 0.03
41 10.05
Allosteric network of dynamic coupling within BAP1-UCH revealed by methyl NMR 0.11
Resolving thyroid lineage cell trajectories merging into a dual endocrine gland in mammals 0.13
Naïve CD4+ T-cells and disease status at CART infusion correlate with clinical outcomes in real-world large B-cell lymphoma patients receiving second-line CAR T therapy 0.03
Nivolumab plus ipilimumab for chemotherapy-refractory metastatic castration-resistant prostate cancer: results from the randomized portion of the phase 2 CheckMate 650 trial 0.03
CD84 is a specific target for acute myeloid leukemia CAR-T cell therapy 0.92
Spatial predictors of response to chemo-immunotherapy in microsatellite stable metastatic colorectal cancer 0.33
Genetic determinants of fatigue up to 2 years after radiotherapy in prostate cancer patients 0.09
Vitamin D binding protein induces skeletal muscle atrophy and contributes to cancer-associated muscle wasting independently of vitamin D status in preclinical models 0.93
Balancing the efficacy and safety of chimeric antigen receptor T-cell therapy by affinity combination 0.04
Tazemetostat, an EZH2 inhibitor, in solid tumors harboring SWI/SNF alterations: a phase II basket study 0.06
First-line Nivolumab plus FOLFOXIRI/Bevacizumab in advanced RAS/BRAF-mutated colorectal cancer: efficacy, safety and biomarker discovery from the phase II NIVACOR trial 1.00
Durvalumab and cediranib with and without olaparib in recurrent ovarian cancer: a phase II proof-of-concept study 0.03
Clonal evolutionary analysis reveals patterns of malignant transformation of Intraductal Papillary Mucinous Neoplasms of the pancreas 0.37
Mast-cell derived nerve growth factor drives ILC2 pro-tumoral functions in bladder cancer 0.13
Combined targeted and epigenetic-based therapy enhances antitumor immunity by stabilizing GATA6-dependent MHCI expression in pancreatic ductal adenocarcinoma 0.07
Leveraging glucan-induced trained immunity for the epigenetic and metabolic rewiring of macrophages to enhance colorectal cancer vaccine response 0.09
The functional landscape of alternative splicing in hematopoietic lineage commitment 0.06
CXCR4 induces memory formation over exhaustion in CAR-T cells to achieve durable leukemia targeting 0.01
Tucatinib plus trastuzumab for chemotherapy-refractory, HER2 + , RAS wild-type metastatic colorectal cancer (MOUNTAINEER): final analysis 0.09
Expression of antibody-drug conjugate targets in post-mortem samples of breast cancer metastases and normal tissue 0.02
Cancer stage at diagnosis by duration of pre-existing chronic analgesic use and anxiety or depression 0.08
Aberrant cytoplasmic localization of MLH1 characterizes a cell population that seeds breast cancer recurrence 0.44
Predictive models of melanoma metastasis based on dermatoscopy in an international retrospective human reader study 0.17
Non-small cell lung cancer molecular subtypes and vulnerability to immunotherapy treatment combinations 0.05
ctDNA detectability and representativeness in seven body liquids from patients with metastatic breast cancer 0.02
MCL1 modulates mTORC1 signaling to promote bioenergetics and tumorigenesis 0.11
Deciphering the role of complement system genes in pancreatic cancer susceptibility and prognosis 0.04
Human iPSCs-based modeling unveils SETBP1 as a driver of chromatin rewiring in GATA2 deficiency 0.01
Pathogenic variants in cause an X-linked neurodevelopmental disorder modulated by NURF complex composition 0.05
Chromatin remodeling restrains oncogenic functions in prostate cancer 1.00
Inflammation and mutational burden differentially associated with nivolumab or ipilimumab combination efficacy in colorectal cancer 0.13
Ataluren improves hematopoietic and pancreatic disorders in Shwachman-Diamond syndrome patients: a compassionate program case-series 0.90
The HDAC inhibitor romidepsin renders liver cancer vulnerable to RTK targeting and immunologically active 0.08
Polyclonal expansion of functional tumor-reactive lymphocytes infiltrating glioblastoma for personalized cell therapy 0.99
LncRNA is altered in human cardiomyopathies and promotes stem cell-derived cardiomyogenesis via splicing regulation 1.00
Prolonging lung cancer response to EGFR inhibition by targeting the selective advantage of resistant cells 0.06
Small round cell sarcoma tumoroid biobank reveals CIC::DUX4 sarcoma vulnerability to MCL-1 inhibition 0.04
Integrated molecular and clinical characterization of pulmonary large cell neuroendocrine carcinoma 0.04
A humanized anaplastic lymphoma kinase (ALK)-directed antibody-drug conjugate with pyrrolobenzodiazepine payload demonstrates efficacy in ALK-expressing cancers 0.06
Longitudinal circulating tumor DNA analysis during treatment of locally advanced resectable gastric or gastroesophageal junction adenocarcinoma: the PLAGAST prospective biomarker study 0.02
TRF1 relies on fork reversal to prevent fragility at human telomeres 0.22
5 1.17
High-resolution single-cell mapping of clonal hematopoiesis and structural variation in aplastic anemia 0.01
Tumor DNA methylation subtypes predict immunotherapy outcomes in pleural mesothelioma patients in the NIBIT-EPI-MESO study 0.87
Biallelic variants in cause the most prevalent known recessive neurodevelopmental disorder 0.17
De novo and inherited dominant variants in U4 and U6 snRNA genes cause retinitis pigmentosa 0.06
Telomere attrition becomes an instrument for clonal selection in aging hematopoiesis and leukemogenesis 0.06
1 0.09
Restoring the tumour mechanophenotype of vocal fold cancer reverts its malignant properties 0.09
17 5.52
Isatuximab, carfilzomib, lenalidomide and dexamethasone in newly diagnosed multiple myeloma: a randomized phase 3 trial 0.25
Enhanced dynamic risk stratification of smoldering multiple myeloma 0.10
First-line zolbetuximab plus mFOLFOX6 and nivolumab in unresectable CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: a phase 2 trial 0.16
Anti-CD19 CAR T cells for pediatric patients with treatment-refractory autoimmune diseases 0.70
Fecal microbiota transplantation plus pembrolizumab and axitinib in metastatic renal cell carcinoma: the randomized phase 2 TACITO trial 0.91
Neoadjuvant ipilimumab plus nivolumab in melanoma: 5-year survival and biomarker analysis from the phase 2 PRADO-trial 0.00
Nous-209 neoantigen vaccine for cancer prevention in Lynch syndrome carriers: a phase 1b/2 trial 0.28
Soluble MAdCAM-1 as a biomarker in metastatic renal cell carcinoma 0.12
CD19 CAR-T cells for treatment-refractory autoimmune diseases: the phase 1/2 CASTLE basket trial 0.11
Adjuvant nivolumab and relatlimab in stage III/IV melanoma: the randomized phase 3 RELATIVITY-098 trial 0.08
Trastuzumab deruxtecan in HER2-low metastatic breast cancer: long-term survival analysis of the randomized, phase 3 DESTINY-Breast04 trial 0.04
Genomically matched therapy in advanced solid tumors: the randomized phase 2 ROME trial 1.00
Neoadjuvant PD-1 and LAG-3-targeting bispecific antibody and other immune checkpoint inhibitor combinations in resectable melanoma: the randomized phase 1b/2 Morpheus-Melanoma trial 0.12
GD2-targeting CAR T cells in high-risk neuroblastoma: a phase 1/phase 2 trial 1.00
Adjuvant nivolumab in muscle-invasive urothelial carcinoma: exploratory biomarker analysis of the randomized phase 3 CheckMate 274 trial 0.06
Atezolizumab plus paclitaxel and bevacizumab as first-line treatment of advanced triple-negative breast cancer: the ATRACTIB phase 2 trial 0.08
Pooled analysis of 3,741 stool metagenomes from 18 cohorts for cross-stage and strain-level reproducible microbial biomarkers of colorectal cancer 0.53
1 0.11
Iron–silver-modified quantum dots act as efficient catalysts in anti-cancer multitherapy through controlled, ultrasound-induced oxidation 0.11
1 0.17
Heterochromatin boundaries maintain centromere position, size and number 0.17
1 1.00
TERT translocation to mitochondria: Exploring its role in mitochondrial homeostasis. 1.00
9 3.83
Fra-2 controls the response to the KRAS inhibitor MRTX-1133 in pancreatic ductal adenocarcinoma 0.78
Spatial transcriptomics reveals tumor microenvironment–driven subtypes of invasive lobular carcinoma 0.05
Integrated mutational landscape analysis of endometrial stromal sarcoma 0.42
Controlled dynamic remodeling of the spliceosome active site enables the first step of splicing 0.45
Biliverdin reductase A is a major determinant of protective NRF2 signaling 0.05
The WWP1–JARID1B axis sustains acute myeloid leukemia chemoresistance 0.80
p63 and ZNF148 cooperate to regulate head and neck squamous cell carcinoma 0.98
PIK3CA gain-of-function mutation in Schwann cells leads to severe neuropathy and aerobic glycolysis through a non-cell autonomous effect 0.08
The cell-permeable iron chelator M606 inhibits MYCN-driven neuroblastoma via an E2F3-mediated response 0.23
3 1.64
Tumor Involvement of the Nipple at Preoperative Contrast-enhanced Mammography: A Multicenter Diagnostic Accuracy Study. 0.60
External Test of a Deep Learning Algorithm for Pulmonary Nodule Malignancy Risk Stratification Using European Screening Data. 0.11
Histopathologic Yields and Concordance of In-Bore MRI-targeted Biopsy for Prostate Cancer Diagnosis. 0.93
1 0.18
Lymphoid tissue chemokines limit priming duration to preserve CD8+ T cell functionality 0.18
5 2.41
HnRNP C binding to inverted Alu elements protects the transcriptome from pre-mRNA circularization 0.87
A synergistic interaction between PRMT5 and LSD1 inhibitors in AML 0.31
Accessory microRNA byproducts expand RNA interference via microprocessor-mediated cleavage activation 0.17
Small-molecule OPA1 inhibitors reverse mitochondrial adaptations to overcome therapy resistance in acute myeloid leukemia 0.24
Small molecule OPA1 inhibitors amplify cytochrome c release and reverse cancer cells resistance to Bcl-2 inhibitors 0.83
4 1.39
Dual-positive CTCs in patients with advanced breast cancer show metastatic potential and prognostic value 0.24
Chimeric antigen receptor T cells against the IGHV4-34 B cell receptor specifically eliminate neoplastic and autoimmune B cells 0.06
A cross-talk established by tumor-targeted cytokines rescues CAR T cell activity and engages host T cells against glioblastoma in mice 1.00
Podocyte YAP and TAZ hyperactivation drives glomerular epithelial proliferative diseases in mice and humans 0.09
5 1.21
NGFR induces melanoma invasion and immunotherapy resistance through myosin light chain 2 modulation 0.05
Chromosomal instability promotes cell migration and invasion via EFEMP1 secretion into extracellular vesicles 0.06
Pervasive phenotypic effects of FBXO42 are promoted by regulation of PP4 phosphatase 0.08
Non-cell-autonomous control of mouse gastruloid development by the ultra-conserved lncRNA T-UCstem1 0.89
CHD8 interacts with BCL11A to induce oncogenic transcription in triple negative breast cancer 0.13
1 1.00
Exploring Disordered Regions of Human Spliceosome Proteins 1.00
10 1.71
Progress towards the WHO Global Initiative for Childhood Cancer target of 60% 5-year survival for all childhood cancers combined, 1990–2019 (CONCORD-4): a Cancer Survival Index derived for 68 countries by analysis of individual records for 613 021 children from 307 population-based cancer registries 0.11
Pimicotinib versus placebo for tenosynovial giant cell tumour (MANEUVER): an international, randomised, placebo-controlled, phase 3 trial 0.08
Lisocabtagene maraleucel in patients with relapsed or refractory marginal zone lymphoma (TRANSCEND FL): primary analysis results from the global, multicohort, single-arm, phase 2 study 0.07
Preoperative mFOLFIRINOX versus PAXG for stage I–III resectable and borderline resectable pancreatic ductal adenocarcinoma (PACT-21 CASSANDRA): results of the first randomisation analysis of a randomised, open-label, 2 × 2 factorial phase 3 trial 0.96
Global variation in patterns of care and time to initial treatment for breast, cervical, and ovarian cancer from 2015 to 2018 (VENUSCANCER): a secondary analysis of individual records for 275 792 women from 103 population-based cancer registries in 39 countries and territories 0.10
Adagrasib versus docetaxel in KRAS G12C-mutated non-small-cell lung cancer (KRYSTAL-12): a randomised, open-label, phase 3 trial 0.14
Talazoparib plus enzalutamide in men with HRR-deficient metastatic castration-resistant prostate cancer: final overall survival results from the randomised, placebo-controlled, phase 3 TALAPRO-2 trial 0.05
Talazoparib plus enzalutamide in men with metastatic castration-resistant prostate cancer: final overall survival results from the randomised, placebo-controlled, phase 3 TALAPRO-2 trial 0.05
Retifanlimab with carboplatin and paclitaxel for locally recurrent or metastatic squamous cell carcinoma of the anal canal (POD1UM-303/InterAACT-2): a global, phase 3 randomised controlled trial 0.10
Efficacy and safety of selumetinib in adults with neurofibromatosis type 1 and symptomatic, inoperable plexiform neurofibromas (KOMET): a multicentre, international, randomised, placebo-controlled, parallel, double-blind, phase 3 study 0.05
1 0.33
Thyroid cancer in adolescents and young adults: a population-based study in 185 countries worldwide 0.33
27 5.46
Bayesian sequential learning for prognostication in extremity soft tissue sarcoma (BayeSarc): a retrospective, multicentre cohort study 0.39
CDK4/6 inhibitors plus endocrine therapy versus endocrine monotherapy in hormone receptor-positive, HER2-negative advanced breast cancer: a reconstructed individual patient data meta-analysis of phase 3 randomised controlled trials 0.14
Lymph node surgery and CDK4/6 inhibitors in early breast cancer: a pooled analysis from five randomised trials 0.10
Fulzerasib plus cetuximab in first-line KRASG12C-mutated non-small-cell lung cancer (KROCUS): a single-arm, multicentre, phase 1b/2 trial 0.24
Neoadjuvant sacituzumab govitecan plus pembrolizumab, followed by adjuvant pembrolizumab, in patients with muscle-invasive bladder cancer (SURE-02): a single-arm, phase 2 study 0.76
Vibostolimab coformulated with pembrolizumab versus pembrolizumab alone as adjuvant therapy for high-risk stage IIB–IV melanoma (KEYVIBE-010): a randomised, double-blind, phase 3 study 0.04
Metastasis-directed therapy and standard of care versus standard of care for oligometastatic prostate cancer (WOLVERINE): a systematic review and individual patient data meta-analysis from the X-MET collaboration 0.25
Inter-rater reliability of CTCAE assessments with or without EORTC patient-reported outcome data in a mixed cancer population: a multinational, open-label, randomised controlled trial 0.05
Cilta-cel in lenalidomide-refractory multiple myeloma (CARTITUDE-4): an updated analysis including overall survival from an open-label, multicentre, randomised, phase 3 trial 0.03
Oncological outcomes with and without axillary lymph node dissection in patients with residual micrometastases after neoadjuvant chemotherapy (OPBC-07/microNAC): an international, retrospective cohort study 0.09
Concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): final and exploratory analyses of a randomised, open-label, phase 3 trial 0.05
Distant disease-free survival as a surrogate endpoint for overall survival in randomised trials of neoadjuvant therapy for early breast cancer: a pooled analysis of GBG and AGO-B Study Group trials 0.22
A prognostic classification system for extent of resection in IDH-mutant grade 2 glioma: an international, multicentre, retrospective cohort study with external validation by the RANO resect group 0.14
Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): final analysis of a randomised, open-label, international, phase 3 study 0.03
Total neoadjuvant therapy followed by non-operative management or surgery in stage II–III rectal cancer (NO-CUT): a multicentre, single-arm, phase 2 trial 1.00
Vorasidenib in IDH1-mutant or IDH2-mutant low-grade glioma (INDIGO): secondary and exploratory endpoints from a randomised, double-blind, placebo-controlled, phase 3 trial 0.03
First-line immunotherapy with or without chemotherapy versus BRAF plus MEK inhibitors in BRAF V600E-mutated metastatic non-small-cell lung cancer (FRONT-BRAF): a multicentre, retrospective cohort study 0.27
Long-term overall survival with dual CTLA-4 and PD-L1 or PD-1 blockade and biomarker-based subgroup analyses in patients with advanced non-small-cell lung cancer: a systematic review and reconstructed individual patient data meta-analysis 0.54
Genetic modification of the AJCC classification of papillary thyroid cancer: an international, multicentre, retrospective cohort study 0.15
Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): 10-year clinical outcomes and post-hoc analysis by molecular classification from a randomised phase 3 trial 0.10
Lenvatinib plus pembrolizumab in pretreated metastatic B3 thymoma and thymic carcinoma (PECATI): a single-arm, phase 2 trial 0.15
TAR-200 plus cetrelimab versus cetrelimab monotherapy as neoadjuvant therapy in patients with muscle-invasive bladder cancer who are ineligible for or decline neoadjuvant cisplatin-based chemotherapy (SunRISe-4): interim analysis of a randomised, open-label phase 2 trial 0.05
Health-related quality of life in patients with KRAS G12C-mutated chemorefractory metastatic colorectal cancer treated with sotorasib plus panitumumab or standard of care (CodeBreaK 300): results from a phase 3, randomised clinical trial 0.21
Long-term survival and cure fraction estimates for paediatric central nervous system tumours in 31 European countries (EUROCARE-6): a population-based study 0.20
Belantamab mafodotin plus bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-7): updated overall survival analysis from a global, randomised, open-label, phase 3 trial 0.05
HER2DX and survival outcomes in early-stage HER2-positive breast cancer: an individual patient-level meta-analysis 0.12
Cabozantinib plus atezolizumab in metastatic prostate cancer (CONTACT-02): final analyses from a phase 3, open-label, randomised trial 0.05
15 1.26
First-Line Sunvozertinib in NSCLC with EGFR Exon 20 Insertion Mutations 0.07
Teclistamab in Multiple Myeloma with One to Three Previous Lines of Therapy 0.08
Zanidatamab with and without Tislelizumab in HER2-Positive Gastroesophageal Cancer 0.03
Palbociclib for Hormone-Receptor–Positive, HER2-Positive Advanced Breast Cancer 0.03
Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma 0.05
European Study of Prostate Cancer Screening — 23-Year Follow-up 0.13
ctDNA-Guided Adjuvant Atezolizumab in Muscle-Invasive Bladder Cancer 0.18
Improved Survival with Enzalutamide in Biochemically Recurrent Prostate Cancer 0.05
Sacituzumab Govitecan in Untreated, Advanced Triple-Negative Breast Cancer 0.06
Nivolumab for Resected Stage III or IV Melanoma at 9 Years 0.21
Sevabertinib in Advanced HER2-Mutant Non–Small-Cell Lung Cancer 0.14
Overall Survival with Amivantamab–Lazertinib in EGFR-Mutated Advanced NSCLC 0.05
Tarlatamab in Small-Cell Lung Cancer after Platinum-Based Chemotherapy 0.04
First-Line Camizestrant for Emerging ESR1-Mutated Advanced Breast Cancer 0.04
Trastuzumab Deruxtecan or Ramucirumab plus Paclitaxel in Gastric Cancer 0.12

Numerical information only (in the tables above) is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International.